title: The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
abstract: Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.
authors.affiliation: Oncotherapeutics, West Hollywood, CA, USA.
authors.forename: Claudia V
authors.initials: CV
authors.lastname: Andreu-Vieyra
authors.affiliation: Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA 90069, USA.
authors.forename: James R
authors.initials: JR
authors.lastname: Berenson
keywords: histone deacetylase inhibitor; multiple myeloma; panobinostat